NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

坐骨神經痛:流行病學預測(2030年)

Sciatica - Epidemiology Forecast-2030

出版商 DelveInsight Business Research LLP 商品編碼 960899
出版日期 按訂單生產 內容資訊 英文 80 Pages
商品交期: 10個工作天內
價格
坐骨神經痛:流行病學預測(2030年) Sciatica - Epidemiology Forecast-2030
出版日期: 按訂單生產內容資訊: 英文 80 Pages
簡介

2017年,七個主要市場的坐骨神經痛的患病率為27,022,660。 2017年,腰椎間盤突出症的患病率為7,358,250,預計在預測期內將增加。 2017年,符合美國手術條件的患者人數為1,082,736,預計在預測期內將增加。

該報告詳細介紹了美國七個主要市場,五個歐洲國家(德國,法國,意大利,西班牙和英國)和日本的坐骨神經痛市場,以及SWOT分析,疾病風險和負擔,我們提供有關未滿足需求,高患病率,診斷和治療數量的信息。

目錄

第1章主要見識

第2章執行摘要

第3章SWOT分析

第4章坐骨神經痛流行病概述

  • 2017年:坐骨神經痛患者所佔比例(%)
  • 2030年:坐骨神經痛患者所佔比例(%)

第5章疾病背景和概述:坐骨神經痛

  • 簡介
  • 坐骨神經痛和下背部疼痛的區別
  • 坐骨神經痛的症狀
  • 坐骨神經痛的原因
    • 椎間盤疝
    • 椎管狹窄
    • 懷孕
    • 梨肌綜合症
    • 退行性關節炎
    • 脊椎病和腰椎滑脫
    • 非致成因的原因
  • 椎間盤相關性坐骨神經痛的病理生理學
    • 臨床觀察
    • 坐骨神經痛的生理變化
  • 腸痛的病理生理機制
    • 炎症機制
    • 免疫學機制
    • 壓縮機制
    • 腰椎管狹窄
    • 神經根損傷的骨骼原因
    • 腰或椎間盤突出症
  • 預後
  • 坐骨神經痛的生物標誌物
  • 坐骨神經痛的診斷
    • 坐骨神經痛指數
    • 成像
    • 選擇性神經根阻滯(SRNB)
  • 鑑別診斷
  • 診斷坐骨神經痛的臨床指南
    • 診斷一般常規的臨床指南
  • 診斷算法
  • 預防坐骨神經痛

第6章許可設施

第7章治療

  • 坐骨神經痛的非手術治療
    • 物理療法
    • 心理療法
    • 毒品
  • 坐骨神經痛的手術治療

第8章美國醫學會(ACP)腰痛治療指南

  • 證據評級和提出建議
  • 藥物治療的相對優勢
  • 非藥物治療的相對優勢
  • 建議

英國國家醫療技術評估組織(NICE)的第9章治療指南

第10章流行病學和患者人群

  • 主要發現
  • 流行病學調查方法
  • 七個主要國家的坐骨神經痛總患病率

第11章坐骨神經痛的流行病學:按國家分類

  • 美國
    • 假設和依據
    • 坐骨神經痛在美國的患病率
    • 在美國診斷坐骨神經痛的患病率
    • 坐骨神經痛在美國的患病率:按病因
    • 坐骨神經痛在美國的患病率:性別
    • 在美國坐骨神經痛的患病率:按年齡
    • 符合美國手術條件的患者庫
  • 歐盟5個國家
  • 德國
    • 德國坐骨神經痛的患病率
    • 德國坐骨神經痛的診斷患病率
    • 德國坐骨神經痛的患病率:按病因
    • 坐骨神經痛在德國的患病率:性別
    • 德國坐骨神經痛的患病率:按年齡分組
    • 符合德國手術條件的患者庫
  • 法國
  • 意大利
  • 西班牙
  • 英國
    • 坐骨神經痛在英國的患病率
    • 英國坐骨神經痛的診斷患病率
    • 坐骨神經痛在英國的患病率:按病因
    • 坐骨神經痛在英國的患病率:性別
    • 坐骨神經痛在英國的患病率:按年齡劃分
    • 符合英國手術條件的患者庫
  • 日本
    • 假設和依據

第12章附錄

第13章:Delve Insight服務內容

第14章免責聲明

第15章:關於Delve Insight

目錄
Product Code: DIEI0392

DelveInsight's 'Sciatica-Epidemiology Forecast-2030' report delivers an in-depth understanding of the disease, historical and forecasted Sciatica epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Sciatica Understanding

Sciatica is a pain in the lower extremity resulting from irritation of the sciatic nerve. The pain of Sciatica is typically felt from the low-back (lumbar area) to behind the thigh and can radiate down below the knee. The sciatic nerve is the largest nerve in the body and begins from nerve roots in the lumbar spinal cord in the low back and extends through the buttock area to send nerve endings down the lower limb. Radiculopathy is sometimes referred to as sciatic nerve pain. Sciatica is an unbearable condition in which the patient experiences pain and/or paresthesia in the supply of the sciatic nerve or linked lumbosacral nerve root. Sciatica is a specific pain that is a direct result of sciatic nerve or sciatic nerve root pathology. The term sciatica is limited to the pain and irritation in nerve roots from L1 to L4 and may also involve related areas. Many times patients and clinicians use Sciatica to describe any pain arising from the lower back and radiating down to the leg.

There are some major risk factors associated with the patient for the initiation of the disease and further progression. Some of them are personal factors which involve that the peak age of the disease occurrence is between 45 and 64 years. Smoking and mental health are not only of the causes but also major factors for the progression of the disease. Occupational factors include strenuous physical activity, for example, frequent lifting, especially while bending and twisting. Driving, including vibration of the whole body can also be one of the minor factors.

Sciatica Epidemiology Perspective by DelveInsight

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Prevalence of Sciatica, Diagnosed Prevalence of Sciatica, Cause-specific Diagnosed Prevalence of Sciatica, Gender-specific Diagnosed Prevalence of Sciatica, Age-specific Diagnosed Prevalence of Sciatica, Surgery eligible patient pool of Sciatica scenario of Sciatica in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.

Sciatica Detailed Epidemiology Segmentation

  • The total prevalent population of Sciatica in the seven major markets ranges was 27,022,660 in 2017
  • Delveinsight has also analyzed the diagnosed prevalent population of lumbar disc herniation. In 2017, the number of diagnosed prevalent cases of lumbar disc herniation was 7,358,250, which will increase in the forecast period.
  • In 2017, it was estimated that 4,802,485 males and 3,373,349 females were found with Sciatica in the United States.
  • In 2017, the surgery eligible patient pool in the US was 1,082,736, which is anticipated to increase in the forecast period.
  • The age-specific prevalence of Sciatica was maximum in the age group 45-54 with 2,043,958 cases in 2017 in the US while the lowest number of cases were found in 18-34 age group with 1,218,199 cases in 2017.
  • In 2017, it was estimated that 4,802,485 males and 3,373,349 females were found with Sciatica in the United States. On the other hand, a similar trend is not observed in EU5, and Japan wherein females are more predominant than males.

Scope of the Report:

  • The report covers the descriptive overview of Sciatica, explaining its causes, signs and symptoms, pathophysiology and currently available therapies.
  • The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan.
  • The report assesses the disease risk and burden and highlights the unmet needs of Sciatica.
  • The report provides the segmentation of the disease epidemiology for 7MM by Total Prevalent Cases of Sciatica, Total Diagnosed and Treated Cases of Sciatica.

Report Highlights:

  • Eleven-Year Forecast of Sciatica
  • 7MM Coverage
  • Prevalence of Sciatica
  • Diagnosed Prevalence of Sciatica
  • Cause-specific diagnosed prevalence of Sciatica
  • Gender-specific Diagnosed Prevalence of Sciatica
  • Age-specific Diagnosed Prevalence of Sciatica
  • Surgery eligible patient pool of Sciatica

Key Questions Answered

  • What is the disease risk, burden and unmet needs of Sciatica?
  • What is the historical Sciatica patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
  • What would be the forecasted patient pool of Sciatica at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Sciatica?
  • Out of the countries mentioned above, which country would have the highest prevalent population of Sciatica during the forecast period (2020-2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2020-2030)?

Reasons to buy:

The Sciatica report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the 7MM Sciatica market.
  • Quantify patient populations in the 7MM Sciatica market to improve product design, pricing, and launch plans.
  • The Sciatica epidemiology report and model were written and developed by Masters and PhD level epidemiologists.
  • The Sciatica epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 11-year forecast period using reputable sources.

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Table of Contents

1 Key Insights

2 Executive Summary

3 SWOT Analysis

4 Sciatica Epidemiology Overview at a Glance

  • 4.1 Patient Share (%) Distribution of Sciatica in 2017
  • 4.2 Patient Share (%) Distribution of Sciatica in 2030

5 Disease Background and Overview: Sciatica

  • 5.1 Introduction
  • 5.2 Difference between Sciatica and Lower Back Pain
  • 5.3 Symptoms of Sciatica
  • 5.4 Causes of Sciatica
    • 5.4.1 Spinal Disc Herniation
    • 5.4.2 Spinal Stenosis
    • 5.4.3 Pregnancy
    • 5.4.4 Piriformis syndrome
    • 5.4.5 Osteoarthritis
    • 5.4.6 Spondylosis and spondylolisthesis
    • 5.4.7 Nondiscogenic causes
  • 5.5 Pathophysiology of disk-related Sciatica
    • 5.5.1 Clinical observation
    • 5.5.2 Physiologic Variants of Sciatica
  • 5.6 Pathophysiological Mechanisms in Radicular Pain
    • 5.6.1 Inflammatory mechanism
    • 5.6.2 Immunological mechanism
    • 5.6.3 Compressive mechanism
    • 5.6.4 Lumbar spinal stenosis
    • 5.6.5 Skeletal Causes of Radiculopathy
    • 5.6.6 Lumbar bulging or herniated disc
  • 5.7 Prognosis
  • 5.8 Biomarkers for Sciatica
  • 5.9 Diagnosis of Sciatica
    • 5.9.1 Indicators for Sciatica
    • 5.9.2 Imaging
    • 5.9.3 Selective Nerve Root Block (SRNB)
  • 5.1 Differential Diagnosis
  • 5.11 Clinical Guidelines for the Diagnosis for Sciatica
    • 5.11.1 Clinical guideline for diagnosis for General Practice
  • 5.12 Diagnostic algorithm
  • 5.13 Prevention of Sciatica

6 Recognized Establishments

7 Treatment

  • 7.1 Nonsurgical Treatment for Sciatica
    • 7.1.1 Physical therapy
    • 7.1.2 Psychological therapies
    • 7.1.3 Medications
  • 7.2 Surgical Treatment of Sciatica

8 The American College of Physicians (ACP) Guidelines for the Treatment of Low Back Pain

  • 8.1 Grading the Evidence and Developing Recommendations
  • 8.2 Comparative Benefits of Pharmacologic Therapies
  • 8.3 Comparative Benefits of Nonpharmacologic Therapies
  • 8.4 Recommendations

9 The National Institute for Health and Care Excellence (NICE) Treatment Guidelines

10 Epidemiology and Patient Population

  • 10.1 Key Findings
  • 10.2 Epidemiology Methodology
  • 10.3 7MM Total Prevalent Population of Sciatica

11 Country Wise-Epidemiology of Sciatica

  • 11.1 United States
    • 11.1.1 Assumption and Rationale
    • 11.1.2 Prevalence of Sciatica in the United States
    • 11.1.3 Diagnosed Prevalence of Sciatica in the United States
    • 11.1.4 Cause-specific Diagnosed Prevalence of Sciatica in the United States
    • 11.1.5 Gender-specific Diagnosed Prevalence of Sciatica in the United States
    • 11.1.6 Age-specific Diagnosed Prevalence in the United States
    • 11.1.7 Surgery Eligible Patient Pool in the United States
  • 11.2 EU5 Countries
    • 11.2.1 Assumption and Rationale
  • 11.3 Germany
    • 11.3.1 Prevalence of Sciatica in Germany
    • 11.3.2 Diagnosed Prevalence of Sciatica in Germany
    • 11.3.3 Cause-specific Diagnosed Prevalence of Sciatica in Germany
    • 11.3.4 Gender-specific Diagnosed Prevalence of Sciatica in Germany
    • 11.3.5 Age-specific Diagnosed Prevalence in Germany
    • 11.3.6 Surgery Eligible Patient Pool in Germany
  • 11.4 France
    • 11.4.1 Prevalence of Sciatica in France
    • 11.4.2 Diagnosed Prevalence of Sciatica in France
    • 11.4.3 Cause-specific Diagnosed Prevalence of Sciatica in France
    • 11.4.4 Gender-specific Diagnosed Prevalence of Sciatica in France
    • 11.4.5 Age-specific Diagnosed Prevalence in France
    • 11.4.6 Surgery Eligible Patient Pool in France
  • 11.5 Italy
    • 11.5.1 Prevalence of Sciatica in Italy
    • 11.5.2 Diagnosed Prevalence of Sciatica in Italy
    • 11.5.3 Cause-specific Diagnosed Prevalence of Sciatica in Italy
    • 11.5.4 Gender-specific Diagnosed Prevalence of Sciatica in Italy
    • 11.5.5 Age-specific Diagnosed Prevalence in Italy
    • 11.5.6 Surgery Eligible Patient Pool in Italy
  • 11.6 Spain
    • 11.6.1 Prevalence of Sciatica in Spain
    • 11.6.2 Diagnosed Prevalence of Sciatica in Spain
    • 11.6.3 Cause-specific Diagnosed Prevalence of Sciatica in Spain
    • 11.6.4 Gender-specific Diagnosed Prevalence of Sciatica in Spain
    • 11.6.5 Age-specific Diagnosed Prevalence in Spain
    • 11.6.6 Surgery Eligible Patient Pool in Spain
  • 11.7 United Kingdom
    • 11.7.1 Prevalence of Sciatica in the United Kingdom
    • 11.7.2 Diagnosed Prevalence of Sciatica in the United Kingdom
    • 11.7.3 Cause-specific Diagnosed Prevalence of Sciatica in the United Kingdom
    • 11.7.4 Gender-specific Diagnosed Prevalence of Sciatica in the United Kingdom
    • 11.7.5 Age-specific Diagnosed Prevalence in the United Kingdom
    • 11.7.6 Surgery Eligible Patient Pool in the United Kingdom
  • 11.8 Japan
    • 11.8.1 Assumptions and Rationale
    • 11.8.2 Prevalence of Sciatica in Japan
    • 11.8.3 Diagnosed Prevalence of Sciatica in Japan
    • 11.8.4 Cause-specific Diagnosed Prevalence of Sciatica in Japan
    • 11.8.5 Gender-specific Diagnosed Prevalence of Sciatica in Japan
    • 11.8.6 Age-specific Diagnosed Prevalence in Japan
    • 11.8.7 Surgery Eligible Patient Pool in Japan

12 Appendix

13 DelveInsight Capabilities

14 Disclaimer

15 About DelveInsight

List of Tables

  • Table 1: Summary of Sciatica, Epidemiology, and Key Events (2017-2030)
  • Table 2: Non-discogenic causes of Sciatica
  • Table 3: Physiologic Variants of Sciatica
  • Table 4: Total Prevalent Population of Sciatica in the 7MM (2017-2030)
  • Table 5: Prevalence of Sciatica in the United States (2017-2030)
  • Table 6: Diagnosed Prevalence of Sciatica in the United States (2017-2030)
  • Table 7: Cause-specific Diagnosed Prevalence of Sciatica in the United States (2017-2030)
  • Table 8: Gender-specific Diagnosed Prevalence of Sciatica in the United States (2017-2030)
  • Table 9: Age-specific Diagnosed Prevalence of Sciatica in the United States (2017-2030)
  • Table 10: Surgery Eligible Patient Pool in the United States (2017-2030)
  • Table 11: Prevalence of Sciatica in Germany (2017-2030)
  • Table 12: Diagnosed Prevalence of Sciatica in Germany (2017-2030)
  • Table 13: Cause-specific Diagnosed Prevalence of Sciatica in Germany (2017-2030)
  • Table 14: Gender-specific Diagnosed Prevalence of Sciatica in Germany (2017-2030)
  • Table 15: Age-specific Diagnosed Prevalence of Sciatica in Germany (2017-2030)
  • Table 16: Surgery Eligible Patient Pool in Germany (2017-2030)
  • Table 17: Prevalence of Sciatica in France (2017-2030)
  • Table 18: Diagnosed Prevalence of Sciatica in France (2017-2030)
  • Table 19: Cause-specific Diagnosed Prevalence of Sciatica in France (2017-2030)
  • Table 20: Gender-specific Diagnosed Prevalence of Sciatica in France (2017-2030)
  • Table 21: Age-specific Diagnosed Prevalence of Sciatica in France (2017-2030)
  • Table 22: Surgery Eligible Patient Pool in France (2017-2030)
  • Table 23: Prevalence of Sciatica in Italy (2017-2030)
  • Table 24: Diagnosed Prevalence of Sciatica in Italy (2017-2030)
  • Table 25: Cause-specific Diagnosed Prevalence of Sciatica in Italy (2017-2030)
  • Table 26: Gender-specific Diagnosed Prevalence of Sciatica in Italy (2017-2030)
  • Table 27: Age-specific Diagnosed Prevalence of Sciatica in Italy (2017-2030)
  • Table 28: Surgery Eligible Patient Pool in Italy (2017-2030)
  • Table 29: Prevalence of Sciatica in Spain (2017-2030)
  • Table 30: Diagnosed Prevalence of Sciatica in Spain (2017-2030)
  • Table 31: Cause-specific Diagnosed Prevalence of Sciatica in Spain (2017-2030)
  • Table 32: Gender-specific Diagnosed Prevalence of Sciatica in Spain (2017-2030)
  • Table 33: Age-specific Diagnosed Prevalence of Sciatica in Spain (2017-2030)
  • Table 34: Surgery Eligible Patient Pool in Spain (2017-2030)
  • Table 35: Prevalence of Sciatica in the United Kingdom (2017-2030)
  • Table 36: Diagnosed Prevalence of Sciatica in the United Kingdom (2017-2030)
  • Table 37: Cause-specific Diagnosed Prevalence of Sciatica in the United Kingdom (2017-2030)
  • Table 38: Gender-specific Diagnosed Prevalence of Sciatica in the United Kingdom (2017-2030)
  • Table 39: Age-specific Diagnosed Prevalence of Sciatica in the United Kingdom (2017-2030)
  • Table 40: Surgery Eligible Patient Pool in the United Kingdom (2017-2030)
  • Table 41: Prevalence of Sciatica in Japan (2017-2030)
  • Table 42: Diagnosed Prevalence of Sciatica in Japan (2017-2030)
  • Table 43: Cause-specific Diagnosed Prevalence of Sciatica in Japan (2017-2030)
  • Table 44: Gender-specific Diagnosed Prevalence of Sciatica in Japan (2017-2030)
  • Table 45: Age-specific Diagnosed Prevalence of Sciatica in Japan (2017-2030)
  • Table 46: Surgery Eligible Patient Pool in Japan (2017-2030)

List of Figures

  • Figure 1: SWOT Analysis of Sciatica
  • Figure 2: The sciatic nerve runs from the back, under the buttock, and downward through the hip area into each leg
  • Figure 3: Types of lumbar disc herniation classification based on the location of the disc herniation relative to the facet joint and spinal canal.
  • Figure 4: Lumbar spinal stenosis is a common cause of Sciatica
  • Figure 5: Piriformis Muscles Syndrome
  • Figure 6: Pathophysiological mechanisms in radicular pain.
  • Figure 7: Pathoanatomical Features of Degenerative Lumbar Spinal Stenosis
  • Figure 8: Algorithm for the diagnostic evaluation of patients with low-back pain.
  • Figure 9: Treatment algorithm of Sciatica
  • Table 10: Adverse events for treatment for Acute, Chronic, and Radicular Low Back Pain
  • Table 11: Adverse events for treatment for Acute, Chronic, and Radicular Low Back Pain
  • Figure 12: Total Prevalent Population of Sciatica in the 7MM (2017-2030)
  • Figure 13: Prevalence of Sciatica in the United States (2017-2030)
  • Figure 14: Diagnosed Prevalence of Sciatica in the United States (2017-2030)
  • Figure 15: Cause-specific Diagnosed Prevalence of Sciatica in the United States (2017-2030)
  • Figure 16: Gender-specific Diagnosed Prevalence of Sciatica in the United States (2017-2030)
  • Figure 17: Age-specific Diagnosed Prevalence of Sciatica in the United States (2017-2030)
  • Figure 18: Surgery Eligible Patient Pool in the United States (2017-2030)
  • Figure 19: Prevalence of Sciatica in Germany (2017-2030)
  • Figure 20: Diagnosed Prevalence of Sciatica in Germany (2017-2030)
  • Figure 21: Cause-specific Diagnosed Prevalence of Sciatica of Sciatica in Germany (2017-2030)
  • Figure 22: Gender-specific Diagnosed Prevalence of Sciatica in Germany (2017-2030)
  • Figure 23: Age-specific Diagnosed Prevalence of Sciatica in Germany (2017-2030)
  • Figure 24: Surgery Eligible Patient Pool in Germany (2017-2030)
  • Figure 25: Prevalence of Sciatica in France (2017-2030)
  • Figure 26: Diagnosed Prevalence of Sciatica in France (2017-2030)
  • Figure 27: Cause-specific Diagnosed Prevalence of Sciatica in France (2017-2030)
  • Figure 28: Gender-specific Diagnosed Prevalence of Sciatica in France (2017-2030)
  • Figure 29: Age-specific Diagnosed Prevalence of Sciatica in France (2017-2030)
  • Figure 30: Surgery Eligible Patient Pool in France (2017-2030)
  • Figure 31: Prevalence of Sciatica in Italy (2017-2030)
  • Figure 32: Diagnosed Prevalence of Sciatica in Italy (2017-2030)
  • Figure 33: Cause-specific Diagnosed Prevalence of Sciatica in Italy (2017-2030)
  • Figure 34: Gender-specific Diagnosed Prevalence of Sciatica in Italy (2017-2030)
  • Figure 35: Age-specific Diagnosed Prevalence of Sciatica in Italy (2017-2030)
  • Figure 36: Surgery Eligible Patient Pool in Italy (2017-2030)
  • Figure 37: Prevalence of Sciatica in Spain (2017-2030)
  • Figure 38: Diagnosed Prevalence of Sciatica in Spain (2017-2030)
  • Figure 39: Cause-specific Diagnosed Prevalence of Sciatica in Spain (2017-2030)
  • Figure 40: Gender-specific Diagnosed Prevalence of Sciatica in Spain (2017-2030)
  • Figure 41: Age-specific Diagnosed Prevalence of Sciatica in Spain (2017-2030)
  • Figure 42: Surgery Eligible Patient Pool in Spain (2017-2030)
  • Figure 43: Prevalence of Sciatica in the United Kingdom (2017-2030)
  • Figure 44: Diagnosed Prevalence of Sciatica in the United Kingdom (2017-2030)
  • Figure 45: Cause-specific Diagnosed Prevalence of Sciatica in the United Kingdom (2017-2030)
  • Figure 46: Gender-specific Diagnosed Prevalence of Sciatica in the United Kingdom (2017-2030)
  • Figure 47: Age-specific Diagnosed Prevalence of Sciatica in the United Kingdom (2017-2030)
  • Figure 48: Surgery Eligible Patient Pool in the United Kingdom (2017-2030)
  • Figure 49: Prevalence of Sciatica in Japan (2017-2030)
  • Figure 50: Diagnosed Prevalence of Sciatica in Japan (2017-2030)
  • Figure 51: Cause-specific Diagnosed Prevalence of Sciatica in Japan (2017-2030)
  • Figure 52: Gender-specific Diagnosed Prevalence of Sciatica in Japan (2017-2030)
  • Figure 53: Age-specific Diagnosed Prevalence of Sciatica in Japan (2017-2030)
  • Figure 54: Surgery Eligible Patient Pool in Japan (2017-2030)